ORLANDO, Fla., May 13, 2016 /PRNewswire/ -- Valensa International announced today that it has completed manufacturing ovo-vegetarian Deep Ocean Caviar™, a first-of-its-kind Omega-3 phospholipid supplement that contains no fish oil. Deep Ocean Caviar™ is derived from North Atlantic Herring Roe (herring eggs) combined with algae-sourced Astaxanthin and Verilla™ vegetarian ALA Perilla Seed Oil, providing a rich source of Omega-3 phospholipids. This formula contains a high DHA-EPA ratio along with ALA Omega-3, and offers powerful support for heart, brain and eye health. Unique and sustainable forms of Omega-3 are the fastest growing segment in the supplement & functional foods markets. Deep Ocean Caviar™ is Valensa's response to this rapidly expanding category.
Valensa's ecological and science-based approach to improving the human condition
According to Dr. Rudi E. Moerck, Valensa CEO, "Valensa's commitment to the environment and human health plus the need to address Chronic Low Level Inflammation (CLLI) was a driving force behind the development of this groundbreaking ecologically sustainable formulation. The Omega-3 ALA and Astaxanthin content of Deep Ocean Caviar™ is squarely aimed at Chronic Low Level Inflammation (CLLI) while the EPA/DHA Phospholipid content targets cellular health and cellular membrane renewal. The incredibly well-managed North Atlantic herring fishery yields herring roe twice a year and is fully sustainable. The addition of EPA/DHA Phospholipids with the necessary and essential ALA Omega-3 creates a totally new approach to fighting CLLI and cellular wellness throughout the human body." Valensa's formulation technology platforms include proprietary extraction (Deep Extract® Supercritical CO2), formulation, delivery / bio-functionality and patented stabilization (O2B® Peroxidation Blocker Stabilization).
Valensa's commitment to product efficacy
According to the Centers for Disease Control, heart disease is the leading cause of death for both men and women. Valensa believes that Chronic Low Level Inflammation (CLLI), a very common condition, is a major factor in heart disease and contributes to a wide variety of other health issues. Says Moerck, "An ecologically-sustainable product to address these multiple needs is long overdue. Valensa's mission to create the most efficacious condition-specific formulas has resulted in Deep Ocean Caviar™."
The Omega-3 fatty acids in Deep Ocean Caviar™ are absorbed and carried to the body's cells in phospholipid and free fatty acid form, enabling optimal bioavailability. Studies show that human cells will readily absorb 95-98% of phospholipids. Valensa's versatile Deep Ocean Caviar™ has FOUR condition-specific applications: brain health, eye health, joint heath, and cardiovascular health and can be customized to meet condition-specific needs.
Valensa's development of sustainable clean source of Omega-3s
Deep Ocean Caviar™ contains no fish oil or shellfish, offers an ultrahigh Omega-3: Omega-6 ratio and is a clean, bioavailable source of DHA and EPA bound phospholipids and Astaxanthin. The complete, clean source formulation includes the addition of Valensa's Zanthin® Natural Astaxanthin and Verilla™ Perilla Seed Oil, to contribute vital ALA Omega-3s for additional functionality and stability as well as anti-inflammatory properties. Deep Ocean Caviar™ has a more favorable DHA to EPA ratio when compared to Krill Oil. In concert with Valensa's strict sustainability policy, the North Atlantic Herring Roe is sourced from an MSC-Certified Wild Sustainable Harvest.
For further information, contact:
Dr. Rudi Moerck, President & CEO